GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuBase Therapeutics Inc (STU:O7P) » Definitions » Retained Earnings

NeuBase Therapeutics (STU:O7P) Retained Earnings : €-109.14 Mil (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is NeuBase Therapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. NeuBase Therapeutics's retained earnings for the quarter that ended in Sep. 2023 was €-109.14 Mil.

NeuBase Therapeutics's quarterly retained earnings declined from Mar. 2023 (€-103.87 Mil) to Jun. 2023 (€-105.83 Mil) and declined from Jun. 2023 (€-105.83 Mil) to Sep. 2023 (€-109.14 Mil).

NeuBase Therapeutics's annual retained earnings declined from Sep. 2019 (€-23.77 Mil) to Sep. 2020 (€-36.98 Mil) and declined from Sep. 2020 (€-36.98 Mil) to Sep. 2021 (€-58.62 Mil).


NeuBase Therapeutics Retained Earnings Historical Data

The historical data trend for NeuBase Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuBase Therapeutics Retained Earnings Chart

NeuBase Therapeutics Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -90.69 -0.04 -23.77 -36.98 -58.62

NeuBase Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -103.77 -101.12 -103.87 -105.83 -109.14

NeuBase Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


NeuBase Therapeutics  (STU:O7P) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


NeuBase Therapeutics (STU:O7P) Business Description

Traded in Other Exchanges
Address
350 Technology Drive, Suite 421, Pittsburgh, PA, USA, 15219
NeuBase Therapeutics Inc is a pre-clinical stage biopharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides. Its Patrol platform is focused on the development of drugs for rare genetic diseases such as Huntington's Disease, Myotonic Dystrophy and Familial Parkinson's Disease among others.

NeuBase Therapeutics (STU:O7P) Headlines

No Headlines